PHASE II TRIAL WITH RFS2000 IN PATIENTS (PTS) WITH ADVANCED AND/OR METASTATIC BREAST CANCER (MBC)

被引：0
|
作者：
Sorio, R. [1 ]
Chollet, P. [2 ]
Caponigro, F. [3 ]
Carteni, G. [4 ]
Sealone, S. [1 ]
Crivellari, D. [1 ]
Magri, M. D. [1 ]
Adank, S. J. [5 ]
Veronesi, A. [1 ]
机构：
[1] IRCCS, CRO, Aviano, Italy
[2] Ctr J Perrin, Clermont Ferrand, France
[3] IRCCS, Ist Pascale, Naples, Italy
[4] AO Cardarelli, Naples, Italy
[5] NDDO Oncol, Amsterdam, Netherlands
来源：
ANNALS OF ONCOLOGY | 2004年 / 15卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：18 / 18
页数：1
相关论文
共 50 条
  • [1] A phase II trial with RFS2000 (rubitecan) in patients with advanced non-small cell lung cancer
    Baka, S
    Ranson, M
    Lorigan, P
    Danson, S
    Linton, K
    Hoogendam, I
    Mettinger, K
    Thatcher, N
    EUROPEAN JOURNAL OF CANCER, 2005, 41 (11) : 1547 - 1550
  • [2] A Phase II Trial of Ganetespib: Efficacy and Safety in Patients (pts) with Metastatic Breast Cancer (MBC)
    Jhaveri, K.
    Chandarlapaty, S.
    Lake, D.
    Gilewski, T.
    Drullinsky, P.
    Sugarman, S.
    Wasserheit-Leiblich, C.
    Moynahan, M. E.
    D'Andrea, G.
    Haque, S.
    Patil, S.
    Bauman, L.
    Vukovic, V.
    El-Hariry, I.
    Hudis, C.
    Modi, S.
    CANCER RESEARCH, 2011, 71
  • [3] A phase II trial of docetaxel in patients (PTS) with anthracycline resistant (AR) metastatic breast cancer (MBC)
    Guastalla, JP
    Bonneterre, J
    Fumoleau, P
    Piccart, M
    Tubiana, M
    Chevallier, B
    Nieamann, C
    Alakl, M
    Nichol, A
    Riva, A
    Marty, M
    EUROPEAN JOURNAL OF CANCER, 1995, 31A : 348 - 348
  • [4] Phase II trial of saracatinib in patients (pts) with ER/PR-negative metastatic breast cancer (MBC)
    Traina, T. A.
    Sparano, J. A.
    Caravelli, J.
    Patil, S.
    Abbruzzi, A.
    Hawke, R.
    Bromberg, J.
    Nonemaker, J.
    Norton, L.
    Hudis, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [5] Final results of gemcitabine (G) and epirubicin (E) phase II trial in metastatic breast cancer (MBC) patients (pts).
    Fumoleau, P
    Viens, P
    Dieras, V
    Pujade-Lauraine, E
    Serin, D
    Petit, T
    Espie, M
    Kayitalire, L
    Robert, C
    Pouillart, P
    BREAST CANCER RESEARCH AND TREATMENT, 2002, 76 : S90 - S90
  • [6] Phase II trial of weekly docetaxel (DOC) and prolonged capecitabine (C) in metastatic breast cancer (MBC) patients (pts).
    Shapiro, CL
    Ramaswamy, B
    Rhoades, C
    Kendra, K
    Allen, J
    Hauger, M
    Loughlin, H
    Moore, T
    Villalona, M
    BREAST CANCER RESEARCH AND TREATMENT, 2004, 88 : S203 - S203
  • [7] A phase II study of pemetrexed and doxorubicin in patients with advanced or metastatic breast cancer (MBC)
    Blasinska-Morawiec, M.
    Martin, M.
    Salas, F.
    Falcon, S.
    Rolski, J.
    Ferrari, B. L.
    Guedez, N.
    Simms, L.
    Gulyas, S.
    Melemed, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [8] A phase II study of HER3-DXD in patients (pts) with metastatic breast cancer (MBC)
    Hamilton, E. P.
    Bagegni, N. A.
    Beck, J. T.
    Cultrera, J. L.
    Dosunmu, O.
    Gwin, W. R.
    Heeke, A. L.
    Khoury, K.
    Sellami, D.
    Shastry, M.
    Sternberg, D. W.
    Toppmeyer, D.
    Wright-Browne, V. M.
    Yuan, Y.
    ANNALS OF ONCOLOGY, 2022, 33 : S220 - S220
  • [9] Phase II Trial of Vinorelbine and Sorafenib in Metastatic Breast Cancer (MBC)
    Luu, T.
    Frankel, P.
    Chung, C.
    Mortimer, J.
    Hurria, A.
    Somlo, G.
    CANCER RESEARCH, 2010, 70
  • [10] Final results of a phase II clinical and pharmacokinetical trial with oral idarubicin (IDA) in elderly patients (pts) with metastatic breast cancer (MBC).
    Crivellari, D
    Lombardi, D
    Sorio, R
    La Mura, N
    Massacesi, C
    Lucenti, A
    Ferro, A
    Veronesi, A
    Corona, G
    Toffoli, G
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 59S - 59S
12345